Director, CMC Drug Substance Manufacturing

<div class="content-intro"><p>Olema Oncology is <span data-ccp-parastyle="Normal (Web)">a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with </span><span data-ccp-parastyle="Normal (Web)">breast cancer</span><span data-ccp-parastyle="Normal (Web)"> and beyond.</span><span data-ccp-parastyle="Normal (Web)"> </span><span data-ccp-parastyle="Normal (Web)">It’s</span><span data-ccp-parastyle="Normal (Web)"> an exciting time to be part of Team Olema</span><span data-ccp-parastyle="Normal (Web)">,</span><span data-ccp-parastyle="Normal (Web)"> with</span><span data-ccp-parastyle="Normal (Web)"> </span><span data-ccp-parastyle="Normal (Web)">our transfor</span><span data-ccp-parastyle="Normal (Web)">mation into a fully</span><span data-ccp-parastyle="Normal (Web)"> </span><span data-ccp-parastyle="Normal (Web)">integrated oncology company well underway</span><span data-ccp-parastyle="Normal (Web)">, </span><span data-ccp-parastyle="Normal (Web)">t</span><span data-ccp-parastyle="Normal (Web)">op-line data from our lead program expected </span><span data-ccp-parastyle="Normal (Web)">later </span><span data-ccp-parastyle="Normal (Web)">this </span><span data-ccp-parastyle="Normal (Web)">year</span><span data-ccp-parastyle="Normal (Web)">,</span><span data-ccp-parastyle="Normal (Web)"> </span><span data-ccp-parastyle="Normal (Web)">and our first potential commercial launch on the horizon.</span></p> <p><span data-contrast="auto"><span data-ccp-parastyle="Normal (Web)">Our lead product candidate, palazestrant, is a novel, orally available complete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD) currently in two pivotal Phase 3 clinical trials. We expect top-line data from OPERA-01, our ongoing Phase 3 trial of palazestrant as a monotherapy in patients with second- or third-line ER+/HER2- metastatic breast cancer (MBC), in the fall which, if successful, could lead to our first potential approval and commercial launch in 2027. OPERA-02, our Phase